Chinese biopharmaceutical company in Chengdu in Sichuan province, founded in 2013 and listed on the Shanghai STAR market, which develops small molecule medicines for cancer and metabolic disease. Works on deuterated chemistry and protein degradation, with programmes including a deuterated androgen receptor antagonist for prostate cancer, a URAT1 inhibitor for gout and hyperuricaemia and protein degraders, and runs its own discovery chemistry, preclinical research and clinical development in China and the United States.
Aucun commentaire disponible.
Laissez votre note & commentaire